Blinatumomab
astellas,amgen
['leusm']
mrd response in 72% in quest (vs 53% in control), incl 56 vs 14% if mrd+ prior to that consolidation block -&gt; translated into 52% reduction in risk of relapse/41% fewer efs events. subgroup analysis suggests benefit in early mrd neg pts as well (like ecog 1910). #ash22 #leusm 2/2
Leukemia/cell therapy doc & AYA Leukemia Program Leader at @MSKCancerCenter w/ special interest in ALL. Indie rock & Boston sports fan. Opinions=my own.??????